Complexities of Designing a Research Exemption Arti K. Rai Professor, Duke Law School.

Slides:



Advertisements
Similar presentations
Creating a Research Use Exemption that Better Fulfills the Patent Bargain Katherine J. Strandburg DePaul University College of Law (2004 Wisconsin L. Rev.)
Advertisements

SEM21-02 ETSI Seminar 2010 « Legal Considerations » Erik Jansen, LL.M. ETSI Legal Director Copyright © ETSI All rights reserved. ETSI Seminar Sophia.
LEGAL CONSIDERATIONS © ETSI All rights reserved ETSI Seminar 2012.
Collaborative Intellectual Property
The Federal Technology Transfer Process: Licenses and Cooperative Research and Development Agreements ADVANCED LICENSING INSTITUTE AT.
LAPSI 4th Thematic Seminar Muenster, January 27, 2011 Should the information held by research institutions be included in the EU Directive on PSI Re-use?
Negotiating Technology License Agreements Tamara Nanayakkara.
12-13 May 2014 Amsterdam, The Netherlands
Jeffrey P. Cunard CAA Counsel Debevoise & Plimpton February 22, 2003 Getting an Art Journal Online: JSTOR and the Art Bulletin © 2003 Debevoise & Plimpton.
Damages Calculations in Infringement Cases Frank S. Farrell F.S. Farrell, LLC 7101 York Ave., So.; Suite 305 Edina, MN Phone: (952) Fax:
FP7 EC Rules – Groupe recherche 16 January 2006Megan Richards European Community FP7 Participation Rules (Commission proposal adopted )
ASSETS OF COMMUNITY VALUE (ACV) – THE COMMUNITY RIGHT TO BID Presenter’s name ; Kevin Lane Role: Head of Law & Governance Department: Resources (Law &
Review of industry code governance 26 March 2010.
Technology and Economic Development Intellectual Property Issues in Research Jim Baker Director Office of Technology and Economic Development
What You Need to Know About Biosimilars: Products, Recent Deals, IP Issues and Licensing August 2, 2012 Madison C. Jellins 1.
An Economic Analysis of Patent Law Exemption for Research on a Patented Invention Reiko Aoki (Kyushu University, Hitotsubashi University, RIETI) Sadao.
CONFIDENTIAL © 2012 Barnes & Thornburg LLP. All Rights Reserved. This page, and all information on it, is confidential, proprietary and the property of.
Flexible Solicitation Formats in Public Competitive Procurement.
IP Issues in Research Jim Baker, Executive Director Innovation, and Industry Engagement.
BUSINESS STRUCTURES.
Public Norms and Private Ordering: The Contractual Creation of a Biomedical Research Commons Prof. Peter Lee UC Davis School of Law October 4, 2008 Prof.
Innovation Policy in the Patent System: An Administrative Approach Arti K. Rai Duke Law School.
1 Technology Transfer Seminar Series Patent Licensing : A Pathway to Commercialization Karen Hersey Senior Counsel for Intellectual Property, MIT. Ret.
What is Commercialization of IP Josiah Hernandez.
OM 석사 2 학기 이연주 Markets for technology and their implications for corporate strategy Arora et al. (2001)
INTELLECTUAL PROPERTY COPYRIGHTS, PATENTS AND TRADE MARKS.
Current Issues in International Intellectual Property Law Access and Benefit Sharing of Genetic Resources in the Pacific Pacific Science Association Conference.
 Synthetic Biology: Caught between Property Rights, the Public Domain, and the Commons Arti Rai and James Boyle Presented by Pei-Ann Lin May 11, 2011.
Contracting to Preserve Open Science: Lessons for a Microbial Research Commons Prof. Peter Lee UC Davis School of Law October 8, 2009
Update on Article 35 of the Japan Patent Law Yoshi Inaba TMI Associates AIPLA Pre-Meeting, January 28, 2004 La Quinta Resort & Club.
Assuring Fair Access in Licensing of University Technology Are there new strategies? Lita Nelsen Mass. Inst. of Tech. MATTO July, 2007.
Christopher J. Fildes Fildes & Outland, P.C. Derivation Proceedings and Prior User Rights.
Access to Genetic Resources & Traditional Knowledge The Bellagio compulsory cross-licensing proposal for benefit sharing consistent with more competition.
1 FRAND COMMITMENTS AND EU COMPETITION LAW Thomas Kramler European Commission, DG Competition (The views expressed are not necessarily those of the European.
McGraw-Hill/Irwin Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved. Chapter 15 Sales and Lease Contracts: Performance, Warranties,
LEGAL ASPECTS OF DIGITAL LIBRARIES By TALWANT SINGH ADDL DISTT. & SESSIONS JUDGE; DELHI.
International Telecommunication Union New Delhi, India, December 2011 ITU Workshop on Standards and Intellectual Property Rights (IPR) Issues Philip.
International Telecommunication Union New Delhi, India, December 2011 ITU Workshop on Standards and Intellectual Property Rights (IPR) Issues Utsab.
26/28/04/2014 – IP for Innovation HG Dynamic Use of Industrial Property for Innovation Growth, Competitiveness and Market Access Heinz Goddar Boehmert.
Intellectual Property: History and Basics. Thomas Jefferson writes a letter On property: “It is agreed by those who have seriously considered the subject,
The Story of Congressional Patent Reform: When Mancur Olson Happens to Good Ideas.
Intellectual Property Right Bernard Denis, DG-KTT.
Top 10 Legal Minefields A University Perspective October 8, 2009 Catherine Shea Associate University Counsel University of Colorado.
 Reconsideration of the Employee Inventions System in Japan Pre-Meeting AIPLA Mid-Winter Institute January 27, 2015 Orlando Sumiko Kobayashi 1.
Lecture 27 Intellectual Property. Intellectual Property simply defined is any form of knowledge or expression created with one's intellect. It includes.
Miljen Matijašević Office: G10, room 6 (1st floor) Tue, 11:30-12:30.
Privatizing the intellectual commons: Universities and the commercialization of biotechnology Nicholas S. Argyres and Julia Porter Liebeskind Journal of.
 New Employee Invention System & Guidelines therefor in Japan Pre-Meeting AIPLA Mid-Winter Institute January 26, 2016 La Quinta Sumiko Kobayashi 1.
Creative Commons terms and definitions By Chelsey Maton.
Standards and competition policy EU-China Workshop on Application of Anti-monopoly Law in Intellectual Property Area Changsha, 11. – 12. March 2010 Peter.
 Utilization Reporting of Subject Inventions o Identifies potentially (at the time of reporting) promising discoveries using the definitions of.
Access v. Patents: We Still Can’t Get Along Srividhya Ragavan University of Oklahoma Law Center.
American University Washington Colleague of Law October 2010 Judit Rius Sanjuan Knowledge Ecology International (KEI) ACTA: a threat to exceptions and.
Copyright Whose is it? And who benefits?. Copyright: ownership and benefits What kind of right? The individual and society How copyright has grown The.
Stephen S. Korniczky Anti-Suit Injunctions – Leveling the Playing Field When Seeking a FRAND License to Standard-Essential.
Technology Transfer Office
Smallest salable patent practicing unit (SSPPU) and component licensing: Why $1 is not $1? Axel Gautier & Nicolas Petit Liège Université.
International Economics
Summary and Policy Levers
Intellectual Property, Patents, Trademarks, Copyright, and Franchising
Nicholas S. Argyres and Julia Porter Liebeskind
Intellectual Property: History and Basics
INTERCONNECTION GUIDELINES
FTAA and Access to Medicines
Partnering with Business and Industry
IPR in FP7 Bart Janse DG Research A.2.
IPR management in CA and GA
Economics of Injunctions in Patent Law
The Bayh–Dole Act: Where Are We Today?
Gil Ohana Cisco Systems Legal Department
Presentation transcript:

Complexities of Designing a Research Exemption Arti K. Rai Professor, Duke Law School

Research exemption: Stage 1 (e.g., Eisenberg 1989) Non-commercial research use by those who are not ordinary users is exempt Non-commercial research use by those who are not ordinary users is exempt When research becomes commercial, no longer exempt When research becomes commercial, no longer exempt At point that research becomes commercial, have to seek license (discretionary or compulsory) At point that research becomes commercial, have to seek license (discretionary or compulsory)

Problems Have to draw line between what is commercial, what is non-commercial Have to draw line between what is commercial, what is non-commercial Hard to determine who is ordinary user Hard to determine who is ordinary user Could undermine private incentives for developing research tools (e.g. Dupont Oncomouse) Could undermine private incentives for developing research tools (e.g. Dupont Oncomouse)

Dreyfuss Response to Line-Drawing Anyone can invoke research exemption so long as they relinquish all proprietary rights in results of research Anyone can invoke research exemption so long as they relinquish all proprietary rights in results of research Ex: Entity that used receptor research tool would have no right to patent drug Ex: Entity that used receptor research tool would have no right to patent drug Would presumably publish results instead Would presumably publish results instead

University Publishes Results Re: Promising Drug Research tool owner gets no compensation Research tool owner gets no compensation Worse, publication may eliminate ability to patent drug Worse, publication may eliminate ability to patent drug If drug can not be patented, who will take it through FDA-mandated approval process? If drug can not be patented, who will take it through FDA-mandated approval process? Dreyfuss suggests buying back patent right (complex) Dreyfuss suggests buying back patent right (complex)

Research Exemption: Stage 2 (Mueller) Compulsory license for some research tools Compulsory license for some research tools If tool readily available at standard price, then not subject to compulsory license If tool readily available at standard price, then not subject to compulsory license But what if standard price is very high? But what if standard price is very high?

Madey v. Duke Makes clear that there is no exemption for non-profit universities Makes clear that there is no exemption for non-profit universities Suggests that even experimenting on patented invention might be infringement Suggests that even experimenting on patented invention might be infringement Latter assertion hard to square with idea that patents require disclosure Latter assertion hard to square with idea that patents require disclosure

Minimalist Proposals Post-Madey Experimenting on must be exempted (AIPLA) Experimenting on must be exempted (AIPLA) Government assumes liability for suits brought against federally funded researchers (National Academies) Government assumes liability for suits brought against federally funded researchers (National Academies) Norms and low damages are likely to limit suits?? Norms and low damages are likely to limit suits??

Other proposals post- Madey (Strandburg, 2004) Experimenting on is exempt Experimenting on is exempt For experimenting with, compulsory licensing after limited period of property rule regime For experimenting with, compulsory licensing after limited period of property rule regime

Difficulties with Compulsory Licensing Can government actors make valuation decisions? Can government actors make valuation decisions? But perhaps parties can bargain in the shadow of possible government action? But perhaps parties can bargain in the shadow of possible government action?

Royalty-free research exemption for federally funded research For such research, incentives to invent are not a concern For such research, incentives to invent are not a concern Proposal has some congruence with existing norms: universities reserve the right to make research uses for themselves (sometimes others) when they give commercial licenses Proposal has some congruence with existing norms: universities reserve the right to make research uses for themselves (sometimes others) when they give commercial licenses

Counter-arguments B-D sees secure patents, exclusive licensing as crucial for development by private sector B-D sees secure patents, exclusive licensing as crucial for development by private sector Research exemption may undermine development motivation of exclusive licensees Research exemption may undermine development motivation of exclusive licensees But B-D rationale does not apply to all research tools, e.g. widely enabling tools that can be the basis for downstream IPRs But B-D rationale does not apply to all research tools, e.g. widely enabling tools that can be the basis for downstream IPRs

Possible Structure of Exemption NIH has power to determine that particular publicly funded research will be subject to royalty-free research exemption for non-commercial research NIH has power to determine that particular publicly funded research will be subject to royalty-free research exemption for non-commercial research Still hard to draw boundary between commercial, non-commercial but need for accuracy is not as great Still hard to draw boundary between commercial, non-commercial but need for accuracy is not as great

Difficulties Limited in scope Limited in scope Will NIH be able to determine ex ante which projects should be subject to research exemption provision? Will NIH be able to determine ex ante which projects should be subject to research exemption provision? Will NIH become subject to political pressure, lobbying if it is given additional discretion? Will NIH become subject to political pressure, lobbying if it is given additional discretion? Will any statutory change be subject to rent-seeking? Will any statutory change be subject to rent-seeking?

Conclusion Difficult to design statutory research exemption Difficult to design statutory research exemption One of reasons it was better to have case- by-case approach/ambiguity of common law One of reasons it was better to have case- by-case approach/ambiguity of common law Post Madey, common law not an option Post Madey, common law not an option Limiting research exemption to publicly funded research may be useful Limiting research exemption to publicly funded research may be useful